Next Article in Journal
Integrating Primary Care Providers through the Seasons of Survivorship
Previous Article in Journal
A Case of Nivolumab-Induced Acute-Onset Type 1 Diabetes Mellitus in Melanoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 1
10.3747/co.26.4809
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib

by
Barbara Melosky
*,
Parneet Cheema
and
Geoffrey Liu
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(1), 119-120; https://doi.org/10.3747/co.26.4809
Submission received: 3 November 2018 / Revised: 8 December 2018 / Accepted: 12 January 2019 / Published: 1 February 2019

Abstract

No abstract available

Share and Cite

MDPI and ACS Style

Melosky, B.; Cheema, P.; Liu, G. Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib. Curr. Oncol. 2019, 26, 119-120. https://doi.org/10.3747/co.26.4809

AMA Style

Melosky B, Cheema P, Liu G. Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib. Current Oncology. 2019; 26(1):119-120. https://doi.org/10.3747/co.26.4809

Chicago/Turabian Style

Melosky, Barbara, Parneet Cheema, and Geoffrey Liu. 2019. "Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib" Current Oncology 26, no. 1: 119-120. https://doi.org/10.3747/co.26.4809

APA Style

Melosky, B., Cheema, P., & Liu, G. (2019). Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib. Current Oncology, 26(1), 119-120. https://doi.org/10.3747/co.26.4809

Article Metrics

Back to TopTop